华人声音Nature:p53介导“铁死亡”抑制肿瘤进展

2015-03-23 佚名 生物谷

近日,细胞生物学领域著名华人科学家Wei Gu在国际期刊nature在线发表了他们的最新研究进展,他们发现经典肿瘤抑制因子p53能够通过调节细胞胱氨酸代谢以及ROS应答,介导ferroptosis过程,抑制肿瘤生长,拓展了人们对p53功能的新认识。 p53是一种肿瘤抑制基因(tumor suppressor gene),在所有恶性肿瘤中,50%以上会出现该基因的突变。p53介导的细胞周期

近日,细胞生物学领域著名华人科学家Wei Gu在国际期刊nature在线发表了他们的最新研究进展,他们发现经典肿瘤抑制因子p53能够通过调节细胞胱氨酸代谢以及ROS应答,介导ferroptosis过程,抑制肿瘤生长,拓展了人们对p53功能的新认识。

p53是一种肿瘤抑制基因(tumor suppressor gene),在所有恶性肿瘤中,50%以上会出现该基因的突变。p53介导的细胞周期暂停,细胞衰老和凋亡对于抑制肿瘤发展具有重要作用,同时有研究表明p53对细胞代谢活性的调节也是其发挥抗肿瘤作用的一项重要手段。
 
研究人员发现p53能够通过下调胱氨酸/谷氨酸转运蛋白中的关键组成成分SLC7A11的表达抑制细胞对胱氨酸的摄取,并增强细胞对一种非凋亡形式的细胞死亡--"铁死亡"(ferroptosis)过程的敏感性。P53 3KR是p53蛋白的一种乙酰化缺陷突变形式,其不能够诱导细胞周期暂停,衰老和凋亡过程,但完全保留了对SLC7A11表达的调控能力,并能够促使细胞在ROS诱导的应激状态下发生"铁死亡"过程。通过对突变小鼠进行分析,研究人员发现这些p53的非经典活性能够促进胚胎发育以及与MDM2缺失相关的致死。同时,研究人员还发现SLC7A11在人类肿瘤中高表达,其过表达能够抑制ROS诱导的"铁死亡"并减弱p53 3KR介导的对肿瘤生长的抑制作用。
 
这项研究表明p53能够通过调节胱氨酸代谢,ROS应答和"铁死亡"抑制肿瘤生长的新模式,进一步拓展了人们对经典抗肿瘤因子p53的新认识,具有重要意义。

原始出处:

Le Jiang,Ning Kon,Tongyuan Li,Shang-Jui Wang,Tao Su,Hanina Hibshoosh,Richard Baer & Wei Gu.Ferroptosis as a p53-mediated activity during tumour suppression.Nature (2015) doi:10.1038/nature14344.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880555, encodeId=d91418805554f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 03 01:05:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737201, encodeId=ed621e372019d, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Apr 12 07:05:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076652, encodeId=c3fc20e6652aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Jan 10 01:05:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372359, encodeId=005913e2359d4, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581886, encodeId=fe7e1581886ea, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18670, encodeId=48b7186e0f2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Mar 23 13:00:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
    2015-10-03 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880555, encodeId=d91418805554f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 03 01:05:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737201, encodeId=ed621e372019d, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Apr 12 07:05:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076652, encodeId=c3fc20e6652aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Jan 10 01:05:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372359, encodeId=005913e2359d4, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581886, encodeId=fe7e1581886ea, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18670, encodeId=48b7186e0f2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Mar 23 13:00:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880555, encodeId=d91418805554f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 03 01:05:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737201, encodeId=ed621e372019d, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Apr 12 07:05:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076652, encodeId=c3fc20e6652aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Jan 10 01:05:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372359, encodeId=005913e2359d4, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581886, encodeId=fe7e1581886ea, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18670, encodeId=48b7186e0f2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Mar 23 13:00:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880555, encodeId=d91418805554f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 03 01:05:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737201, encodeId=ed621e372019d, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Apr 12 07:05:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076652, encodeId=c3fc20e6652aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Jan 10 01:05:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372359, encodeId=005913e2359d4, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581886, encodeId=fe7e1581886ea, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18670, encodeId=48b7186e0f2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Mar 23 13:00:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
    2015-03-25 zhishijing
  5. [GetPortalCommentsPageByObjectIdResponse(id=1880555, encodeId=d91418805554f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 03 01:05:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737201, encodeId=ed621e372019d, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Apr 12 07:05:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076652, encodeId=c3fc20e6652aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Jan 10 01:05:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372359, encodeId=005913e2359d4, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581886, encodeId=fe7e1581886ea, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18670, encodeId=48b7186e0f2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Mar 23 13:00:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1880555, encodeId=d91418805554f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 03 01:05:00 CST 2015, time=2015-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737201, encodeId=ed621e372019d, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Apr 12 07:05:00 CST 2015, time=2015-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076652, encodeId=c3fc20e6652aa, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Jan 10 01:05:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372359, encodeId=005913e2359d4, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581886, encodeId=fe7e1581886ea, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Wed Mar 25 00:05:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18670, encodeId=48b7186e0f2, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=hbwang006, createdTime=Mon Mar 23 13:00:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
    2015-03-23 hbwang006

    有意思

    0

相关资讯

Elife:20年研究颠覆癌症教条

来自加州大学圣地亚哥医学院的研究人员称,发现在调控细胞周期进程中起至关重要的一种蛋白并非以往认为的导致了一个重要的肿瘤抑制因子失活,而是激活了它。加州大学圣地亚哥医学院细胞和分子医学系教授Steven F. Dowdy博士说:“这一研究发现是我们实验室差不多20年研究工作的结果。它完全颠覆了原来所认为的:在癌症中一种叫做p16-cyclin D的最常见遗传信号通路突变驱动了所有癌细胞中细胞周期进程

Blood:肿瘤抑制因子调节了树突细胞的分化与成熟

近日,来自美国乔治城大学医学中心的研究人员发现,肿瘤抑制因子p15Ink4b调节了传统树突细胞的分化与成熟。相关研究成果于5月24日发表在Blood上。 p15INK4B基因是近年来发现的细胞周期蛋白依赖性激酶抑制因子(CKI)家族中的一个新成员,能抑制多种肿瘤细胞的增殖。研究发现,在急性髓细胞性白血病及其它的髓系疾病,肿瘤抑制因子p15Ink4b频繁的被甲基化而失活。 树突细胞(DCs)作为